CLINICAL_TRIALS
trial_result
· 2016-11-09
Clinical Trial Update: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure [Phase 2]
Summary
Phase 2 trial evaluating the safety of repeat intravenous dosing of serelaxin in adults with chronic heart failure; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2016-11-09